Treatment of Neovacular Age-related Macular Degeneration with Intravitreal Bevacizumab: Efficacy of Three Conecutive Monthly Injection Original Reearch Article

Purpoe To report the efficacy of treatment of neovacular age-related macular degeneration (AMD) with intravitreal bevacizumab (Avatin; Genentech, Inc, outh an Francico, California, UA) when adminitered in a erie of three monthly injection followed by a period of obervation. Deign Retropective cae erie. Method Retropective review of conecutive eye with all choroidal neovacular leion ubtype reulting from neovacular AMD treated with intravitreal bevacizumab. Treatment conited of a par plana injection of 1.25 mg Avatin (0.05 ml bevacizumab at a concentration of 25 mg/ml). Evaluation conited of a complete ophthalmologic examination, including bet-corrected viual acuity (VA) meaurement, ophthalmocopy, and optical coherence tomography. Eye received a erie of three monthly injection followed by a three-month period of obervation. Reult A total of 36 patient (37 eye) received a erie of three conecutive monthly intravitreal injection of bevacizumab. Twenty (54%) of 37 eye had no previou treatment for neovacular AMD in the eye that received bevacizumab. eventeen (46%) of 37 eye had received ome previou treatment before initiation of bevacizumab therapy. Intravitreal Avatin therapy produced an improvement in foveal thickne over time in eye with neovacular AMD. Thi improvement wa utained during the erie of three monthly injection. All eye experienced worening after three month without treatment. No tatitically ignificant effect on VA wa demontrated in thi erie. Concluion Intravitreal bevacizumab therapy produced an improvement in foveal thickne over time in eye with neovacular AMD when one injection wa given each month for three conecutive month. All eye experienced increaed foveal thickening during the ubequent three month without treatment.